-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Neutral on Keros Therapeutics, Raises Price Target to $19

Benzinga·11/28/2025 17:08:06
Listen to the news
B of A Securities analyst Jason Zemansky maintains Keros Therapeutics (NASDAQ:KROS) with a Neutral and raises the price target from $18 to $19.